Trial record 1 of 1 for:
M20-866 | AML | Leipzig, Germany
Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04912063 |
|
Recruitment Status :
Completed
First Posted : June 3, 2021
Last Update Posted : May 25, 2023
|
Sponsor:
AbbVie
Information provided by (Responsible Party):
AbbVie
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how safe lemzoparlimab is and how it moves within the body when used along with azacitidine and/or venetoclax in adult participants with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Adverse events and maximum tolerated dose (MTD) of lemzoparlimab will be assessed.
Lemzoparlimab (TJ011133) is being evaluated in combination with azacitidine and venetoclax for the treatment of acute myeloid leukemia (AML) and with azacitidine with/without venetoclax for myelodysplastic syndrome (MDS). Study doctors place the participants in 1 of 5 groups, called treatment arms. Each group receives a different treatment. Adult participants with a diagnosis of AML or MDS will be enrolled. Around 80 participants will be enrolled in the study in approximately 50 sites worldwide.
Participants will receive lemzoparlimab (IV) once weekly (Q1W), venetoclax oral tablets once daily (QD) for 28 days (AML participants) or 14 days (MDS participants) and Azacitidine by SC or IV route QD for 7 days of each 28-day cycle.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS) | Drug: Lemzoparlimab Drug: Azacitidine Drug: Venetoclax | Phase 1 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 40 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Sequential Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase 1b Dose Escalation Study of Lemzoparlimab in Combination With Venetoclax and/or Azacitidine in Subjects With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) |
| Actual Study Start Date : | June 25, 2021 |
| Actual Primary Completion Date : | May 9, 2023 |
| Actual Study Completion Date : | May 9, 2023 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Familial acute myeloid leukemia with mutated CEBPA
Cytogenetically normal acute myeloid leukemia
Core binding factor acute myeloid leukemia
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Lemzoparlimab + Azacitidine + Venetoclax in AML (Escalation)
Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
Drug: Azacitidine Subcutaneous Injection or Intravenous (IV) Injection/Infusion Drug: Venetoclax Oral Tablet
Other Names:
|
|
Experimental: Lemzoparlimab + Azacitidine + Venetoclax in MDS (Escalation)
Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
Drug: Azacitidine Subcutaneous Injection or Intravenous (IV) Injection/Infusion Drug: Venetoclax Oral Tablet
Other Names:
|
|
Experimental: Lemzoparlimab + Azacitidine in MDS (Escalation)
Lemzoparlimab (TJ011133) co-administered with azacitidine in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
Drug: Azacitidine Subcutaneous Injection or Intravenous (IV) Injection/Infusion |
|
Experimental: Lemzoparlimab + Azacitidine + Venetoclax in AML (Expansion)
Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
Drug: Azacitidine Subcutaneous Injection or Intravenous (IV) Injection/Infusion Drug: Venetoclax Oral Tablet
Other Names:
|
|
Experimental: Lemzoparlimab + Azacitidine + Venetoclax in MDS (Expansion)
Lemzoparlimab (TJ011133) co-administered with azacitidine and venetoclax in expansion cohort in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
Drug: Azacitidine Subcutaneous Injection or Intravenous (IV) Injection/Infusion Drug: Venetoclax Oral Tablet
Other Names:
|
|
Experimental: Lemzoparlimab Monotherapy in AML (Japan Only Escalation)
Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve acute myeloid leukemia (AML) who are ineligible for standard induction therapy.
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
|
|
Experimental: Lemzoparlimab Monotherapy in MDS (Japan Only Escalation)
Lemzoparlimab (TJ011133) administered in escalated doses in participants with treatment-naïve higher-risk myelodysplastic syndrome (MDS).
|
Drug: Lemzoparlimab
Intravenous (IV) Infusion
Other Names:
|
Primary Outcome Measures :
- Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) When Co-administered With Venetoclax and Azacitidine in Participants With Treatment-Naïve Acute Myeloid Leukemia (AML) Ineligible for Standard Induction Therapy [ Time Frame: Up to 30 days after first dose of study drug ]DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.
- DLTs of Lemzoparlimab (TJ011133) When Co-administered With Azacitidine With or Without Venetoclax in Participants With Treatment-Naïve Higher-Risk Myelodysplastic Syndrome (MDS) [ Time Frame: Up to 30 days after first dose of study drug ]DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.
- Dose Limiting Toxicities (DLTs) of Lemzoparlimab (TJ011133) as a Monotherapy in Japanese Participants with Relapsed/Refractory (R/R) AML [ Time Frame: Up to 30 days after first dose of study drug ]DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.
- DLTs of Lemzoparlimab (TJ011133) as a Monotherapy in Japanese Participants with R/R MDS [ Time Frame: Up to 30 days after first dose of study drug ]DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications and occurring during the first 4 weeks after administration of the first dose and that meets additional criteria as described in the protocol.
Secondary Outcome Measures :
- Best Overall Response of Complete Remission (CR) for AML [ Time Frame: Up to approximately 3 years ]Best overall response of complete remission (CR), defined as achieving CR according to modified international working group (IWG) 2003 criteria for AML.
- Best Overall Response of Composite CR (CRc) for AML [ Time Frame: Up to approximately 3 years ]Best overall response of composite CR (CRc), [CR or CR with incomplete blood count recovery (CRi)] according to modified IWG 2003 criteria for AML.
- Best Overall Response of CR or Complete Remission With Partial Hematologic Recovery (CRh) for AML [ Time Frame: Up to approximately 3 years ]Best overall response of CR or CRh, defined according to modified IWG 2003 criteria for AML.
- Duration of Response (DOR) for AML [ Time Frame: Up to approximately 3 years ]Duration of response (DOR), defined for participants who achieve a best overall response, as the time from the first occurrence of response to disease progression/relapse from CR, CRi or CRh or death from disease progression, whichever occurs first.
- Event-Free Survival (EFS) for AML [ Time Frame: Up to approximately 3 years ]Event-free survival (EFS), defined as time from first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to the date of progressive disease (PD), relapse from CR or CRi, treatment failure defined as failure to achieve CR, CRi or MLFS after at least 6 cycles of study treatment, or death from any cause, whichever occurs first.
- Overall Survival (OS ) for AML [ Time Frame: Up to approximately 3 years ]Overall survival (OS), defined as the time from the date of the first dose of any study drug (lemzoparlimab or venetoclax or azacitidine) to death from any cause.
- Best Overall Response of CR, for MDS [ Time Frame: Up to approximately 3 years ]Best overall response of CR per the modified IWG 2006 criteria for MDS.
- Best Overall Response of Marrow-Complete Remission (mCR), for MDS [ Time Frame: Up to approximately 3 years ]Best overall response of marrow-complete remission (mCR), per the modified IWG 2006 criteria for MDS.
- Best Overall Response of CR or PR for MDS [ Time Frame: Up to approximately 3 years ]Best overall response of CR or PR, per the modified IWG 2006 criteria for MDS.
- Best Overall Response of CR or PR or mCR, for MDS [ Time Frame: Up to approximately 3 years ]Best overall response of CR or PR or mCR, per the modified IWG 2006 criteria for MDS.
- Hematologic Improvement (HI), for MDS [ Time Frame: Up to approximately 3 years ]Hematologic improvement (HI), defined as a participant achieving erythroid/platelet/neutrophil responses.
- Red Blood Cell Transfusion Independence (TI), for MDS [ Time Frame: Up to approximately 3 years ]Red blood cell transfusion independence (TI), defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.
- Platelet TI, for MDS [ Time Frame: Up to approximately 3 years ]Platelet TI, defined as a participant who is transfusion dependent at baseline achieved TI post-baseline.
- DOR, for MDS [ Time Frame: Up to approximately 3 years ]DOR, defined for participants who achieve a best overall response, as the time from the first occurrence of response (CR or mCR or PR) to disease progression or death, whichever occurs first.
- Progression Free Survival (PFS), for MDS [ Time Frame: Up to approximately 3 years ]Progression Free Survival (PFS) defined as the time from the date of the first dose of any study drug to PD or death from any cause.
- OS, for MDS [ Time Frame: Up to approximately 3 years ]OS, defined as the time from the date of the first dose of any study drug to death from any cause.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Documented confirmation of acute myeloid leukemia (AML) according to the World Health Organization (WHO) criteria, previously untreated [OR]
- Documented diagnosis of previously untreated de novo myelodysplastic syndrome (MDS) according to the 2017 WHO classification with presence of < 20% bone marrow blasts per marrow biopsy/aspirate.
-
Participants with documented MDS must meet the following disease activity criteria:
- Overall revised international prognostic scoring system (IPSS-R) score > 3 (intermediate, high, or very high);
- Eastern cooperative oncology group (ECOG) performance status of 0 to 2;
- Hematopoietic stem cell transplant (HSCT) ineligible, or participant who chooses not to undergo HSCT.
-
Participants with documented AML with adverse cytogenetic and/or molecular risk, and must be considered ineligible for induction therapy defined by the following:
- >= 75 years of age; [OR]
-
>= 18 to 74 years of age with at least one of the following comorbidities: --- Eastern cooperative oncology group (ECOG) performance status of 2 to 3; --- Cardiac history of congestive heart failure requiring treatment or ejection fraction <= 50% or chronic stable angina;
- Diffusion capacity of lung (DLCO) <= 65% or forced expiratory volume during the first second (FEV1) <= 65%;
- Creatinine clearance >= 30 mL/min to < 45 mL/min;
- Moderate hepatic impairment with total bilirubin > 1.5 to <= 3.0 × upper limit of normal (ULN);
- Any other comorbidity that the physician judges to be incompatible with intensive chemotherapy or the participant declines to receive intensive chemotherapy.
Japan Safety Lead-In Phase:
- Documented confirmation of AML according to WHO criteria, relapsed or refractory (R/R) disease without other standard of care treatments.
- Documented diagnosis of MDS according to the 2017 WHO classification with presence of < 20% bone marrow blasts per marrow biopsy/aspirate, with intermediate- and high-risk relapsed/refractory MDS.
-
Documented MDS must meet the following disease activity criteria:
- ECOG performance status of 0 to 2.
Exclusion Criteria:
- Participants with documented AML with acute promyelocytic leukemia and considered eligible for induction therapy.
-
Participant with documented AML having prior diagnosis of:
-- known active central nervous system involvement with AML.
-
Participants with documented MDS having prior diagnosis of:
- MDS evolving from a pre-existing myeloproliferative neoplasm (MPN);
- MDS/MPN including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, juvenile myelomonocytic leukemia and unclassifiable MDS/MPN.
- History of allogeneic HSCT or solid organ transplantation.
- Previous exposure to anti-CD47 therapies.
-
History of an active malignancy within the past 2 years prior to Screening, with the exception of:
-- Adequately treated carcinoma in situ of the cervix uteri or carcinoma in situ of the breast;
- Adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin;
- Asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy;
- Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent.
- Conditions that could interfere with drug absorption including but not limited to short bowel syndrome.
Japan Safety Lead-In Phase:
- Documented AML have Acute Promyelocytic Leukemia.
-
Participant with documented AML having prior diagnosis of:
-- Chronic myeloid leukemia with or without BCR-ABL1 translocation and AML with BCR-ABL1 translocation.
-
Participants with documented MDS having prior diagnosis of:
- Therapy-related MDS.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04912063
Locations
Show 29 study locations
Sponsors and Collaborators
AbbVie
Investigators
| Study Director: | ABBVIE INC. | AbbVie |
| Responsible Party: | AbbVie |
| ClinicalTrials.gov Identifier: | NCT04912063 |
| Other Study ID Numbers: |
M20-866 2021-000514-41 ( EudraCT Number ) |
| First Posted: | June 3, 2021 Key Record Dates |
| Last Update Posted: | May 25, 2023 |
| Last Verified: | May 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Keywords provided by AbbVie:
|
Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS) Lemzoparlimab TJ011133 ABBV-IMAB-TJC4 Venetoclax |
ABT-199 GDC-0199 VENCLEXTA VENCLYXTO Azacitidine Cancer |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid Leukemia, Myeloid, Acute Preleukemia Myelodysplastic Syndromes Syndrome Disease Pathologic Processes Neoplasms by Histologic Type Neoplasms |
Bone Marrow Diseases Hematologic Diseases Precancerous Conditions Azacitidine Venetoclax Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Enzyme Inhibitors |